Loading company
Curis Inc.
CRIS · Nasdaq · ·
Next earnings: November 5, 2026
$0.82-1.1%Sep 29 close
- 1M
- -44.8%
- 6M
- -92.0%
- 1Y
- -97.5%
- 5Y
- -100.0%
CRIS · Nasdaq · ·
Next earnings: November 5, 2026
$0.82-1.1%Sep 29 close
Curis Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $2.7M | -100.00% |
| Profit | -$8.6M | -$8.6M | +0.14% |
| Profit per share | -$4.02 | -$1.25 | -221.60% |
| Free Cash Flow | -$10.2M | -$12.3M | +16.97% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
Inc. Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, in chronic lymphocytic leukemia (CLL). The Company’s monotherapy and combination studies in acute myeloid leukemia (AML) are substantially complete, with additional funding the Company plans to continue development of emavusertib in AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene Discovery Technologies Limited, has the exclusive license to emavusertib (CA-4948).
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Curis Inc.’s Item 2.02 8-K filed May 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Curis Inc. has no earnings call transcript available.